Benefit Of Abiraterone Acetate Plus Prednisone (AA+P) Added To Androgen Deprivation Therapy (ADT) In Patients With High-Risk, Newly Diagnosed Metastatic Hormone-Sensitive Prostate Cancer (MHSPC): Post Hoc Analysis Of EQ-5D-5L From The Latitude Study

Abstract

compliance rates were high (> 95.0% through Cycle 13 and ≥ 90.0% thereafter through Cycle 47) and similar across treatment groups. Patients with deteriorated EQ-5L VAS: (T7) ADT+AA+P, 61.1%; ADT+PBOs, 67.3%; (T10) ADT+AA+P, 57.5%; ADT+PBOs, 61.6%. Median time to deterioration of EQ-5D-5L VAS: (T7) ADT+AA+P, 9.2 months; ADT+PBOs, 5.6 months (HR = 0.81; 95% CI, 0.70-0.94; p < 0.004); (T10) ADT+AA+P, 12.9 months; ADT+PBOs, 8.3 months (HR = 0.83; 95% CI, 0.72-0.97; p = 0.015). Consistent benefit with ADT+AA+P was found across all subgroups for T7 and T10. ConCluSionS: These results confirm significant delay of degradation of health-related quality of life by adding AA+P to ADT in patients with mHSPC, and are consistent with the significant improvements in overall survival and radiographic progression-free survival observed in LATITUDE.